BioCentury
ARTICLE | Clinical News

Aquinox discontinues development of rosiptor

June 29, 2018 2:46 PM UTC

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said its sole clinical asset, rosiptor (AQX-1125), missed the primary endpoint in the double-blind, international Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The company said it has halted the product’s development and plans to provide guidance on strategic options this year.

In the 433-patient trial, once-daily oral rosiptor did not significantly improve mean maximum daily bladder pain score from baseline to week 12 compared with placebo in the trial’s 341 female patients (p=0.41). The company also said rosiptor did not lead to improvements vs. placebo in a number of sensitivity, subpopulation and secondary endpoint analyses...